| Title | Rifamycin-Resistant Mycobacterium tuberculosis in the Highly Active Antiretroviral Therapy Era: A Report of 3 Relapses with Acquired Rifampin Resistance following Alternate-Day Rifabutin and Boosted Protease Inhibitor Therapy. |
| Author(s) | Jenny-Avital ER, Joseph K |
| Institution | Jacobi Medical Center, and 2New York City Department of Health and Mental Hygiene, Morrisania Chest Clinic, Bronx, New York. |
| Source | Clin Infect Dis 2009 Apr 14. |
| Abstract | Rifamycin-resistant Mycobacterium tuberculosis infection (i.e., by a strain of M. tuberculosis that is only resistant to rifamycins) occurs disproportionately among patients infected with the human immunodeficiency virus (HIV) who have a low CD4 cell count. We observed 3 genetically confirmed cases of relapse with rifamycin-resistant M. tuberculosis infection following concurrent treatment with rifabutin (dosage, 150 mg every other day) and a ritonavir-boosted HIV protease inhibitor during a prior episode of drug-susceptible tuberculosis. Higher doses of rifabutin and a ritonavir-boosted HIV protease inhibitor as treatment for tuberculosis should be studied further. |
| Language | ENG |
| Pub Type(s) | JOURNAL ARTICLE
|
| PubMed ID | 19368504 |
